Spruce Biosciences And HMNC Brain Health Collaborate To Develop Spruce's Investigational Product Candidate, Tildacerfont With HMNC's Companion Diagnostic For Major Depressive Disorder, HMNC To Initiate Phase 2 Study In Q4 2024
Portfolio Pulse from Benzinga Newsdesk
Spruce Biosciences and HMNC Brain Health are collaborating to develop Spruce's investigational product candidate, Tildacerfont, with HMNC's companion diagnostic for Major Depressive Disorder. HMNC will initiate a Phase 2 study in Q4 2024.
June 04, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Spruce Biosciences is collaborating with HMNC Brain Health to develop Tildacerfont for Major Depressive Disorder. A Phase 2 study will begin in Q4 2024.
The collaboration with HMNC Brain Health and the initiation of a Phase 2 study for Tildacerfont in Q4 2024 is a significant development for Spruce Biosciences. This partnership could potentially enhance the company's product pipeline and market position, likely leading to a positive short-term impact on SPRB's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90